DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T. et al
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Lancet Oncol 2013;
14: 117-124 . doi:10.1016/S1470-2045(12)70537-5
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.